Pernix Therapeutics Holdings Inc., of Morristown, N.J., said it commenced a private offering of $120 million aggregate principal amount of its convertible senior notes due 2021. Most of the gross proceeds – about $80.9 million – will be used to finance the cash consideration portion necessary to consummate its previously announced acquisition of the Zohydro (hydrocodone) ER franchise.